The Basics

What Are the Signs and Symptoms of Non-Hodgkin’s Lymphoma?

This content has been reviewed and approved by
James O. Armitage, MD
The Joe Shapiro Professor of Internal Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center

By far the most common manifestation of non-Hodgkin's lymphoma is an enlarged lymph node. A firm, enlarged lymph node (larger than the width of your finger) that lasts for several weeks or increases in size should lead one to see a physician. However, many other manifestations of lymphomas are possible.

Because lymphomas can involve any organ in the body, symptoms of malfunction of those organs can be a sign of lymphoma. Neurologic deficits could be the manifestation of a brain lymphoma, jaundice could be the manifestation of lymphoma involving the liver, shortness of breath could be the manifestation of lymphoma involving the lung, abdominal pain or bleeding could signify lymphoma in the intestinal tract, etc.

Lymphomas can sometimes have symptoms that are not confined to any particular organ. The most common of these is unexplained fatigue. However, fevers, night sweats, weight loss, and severe itching are some of the common symptoms. For a patient with any of these symptoms that persist and are not easily explained, lymphoma is one of the things the physician needs to rule out.
.

This content was last modified on August 15, 2007 .

Latest Non-Hodgkin's Lymphoma News

  • May 14, 2008
    Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
    Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
  • May 8, 2008
    Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
    Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
  • May 5, 2008
    Treanda® Included in NCCN Guidelines for CLL and NHL
    The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Select news items provided by Reuters Health
More Cancer News

Privacy Policy reviewed by TRUSTe

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health
Information:
verify here.

Secure transactions for this website use a thawte certificate to ensure secure transmission of your information.